MLN-9708 - CAS# 1239908-20-3 60262 Smiles: CC1C=CC(=CC=1)C1=CC=C(F)C=C1COC1C=CC(CCC(O)=O)=CC=1

Smiles: CC1C=CC(=CC=1)C1=CC=C(F)C=C1COC1C=CC(CCC(O)=O)=CC=1

Hum Mol Genet

rather than directly by removing iron from the active site

1007/s12020-015-0590-1

MLN-9708 - CAS# 1239908-20-3 60262 Smiles: CC1C=CC(=CC=1)C1=CC=C(F)C=C1COC1C=CC(CCC(O)=O)=CC=1MLN 9708, also known as ixazomib citrate, CAS No. 1239908 20 3, is a prodrug of Ixazomib (MMLN 2238). MLN 9708 is an orally bioavailable second generation proteasome inhibitor (PI) with potential antineoplastic activity. MLN 9708, after hydrolyzing to pharmacologically active MLN2238 (ixazomib), is a next generation proteasome inhibitor with demonstrated preclinical and clinical antimyeloma activity. MLN 9708, compared with bortezomib, has improved